Europe Clinical Trials Market Growth, Size, Trends Analysis - By Phase, By Indication, By Study Design, By Service Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
Europe Clinical Trials Market Introduction and Overview
According to SPER market research, ‘Europe Clinical Trials Market Size- By Phase, By Indication, By Study Design, By Service Type – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Europe Clinical Trials Market is predicted to reach 44.34 billion by 2034 with a CAGR of 7.11%.
Clinical trials represent an essential procedure in the creation of novel therapies or medical devices. These investigations assess new pharmaceuticals, medical devices, or additional therapeutic agents, establishing a scientific foundation for efficient patient care while determining the safety and effectiveness of these innovations. The surge in research and development efforts by pharmaceutical and biotechnology firms around the globe has resulted in a rise in the number of clinical studies.
Restraints:
A significant challenge faced by the European clinical trials market is the intricate nature of regulatory approval procedures. Countries within the European Union differ in their regulations, which can cause delays and elevate costs for pharmaceutical companies attempting to conduct clinical trials across several European countries. Despite initiatives aimed at harmonizing regulatory standards, such as those led by the European Medicines Agency (EMA), the variation in national regulations and bureaucratic obstacles continue to present substantial challenges.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Phase, By Indication, By Study Design, By Service Type
Regions covered
IQVIA HOLDINGS, INC, PAREXEL International Corporation, Pharmaceutical Product Development,
Companies Covered
IQVIA HOLDINGS, INC, PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC., Syneos Health Inc, Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Inc., Dr. Notghi Contract Research GmbH, Charite Research Organisation GmbH, Janssen Global Services, LLC, Mondosano GmbH, KFGN.
Europe Clinical Trials Market Segmentation:
By Phase: Based on the Phase, Europe Clinical Trials Market is segmented as; Phase I, Phase II, Phase III, Phase IV.
By Study Design: Based on the Study Design, Europe Clinical Trials Market is segmented as; Interventional studies, Observational studies, Expanded access studies.
By Indication: Based on the Indication, Europe Clinical Trials Market is segmented as; Autoimmune/inflammation, Pain management, Oncology, CNS conditions, Diabetes, Obesity, Cardiovascular, Others.
By Service Type: Based on the Service Type, Europe Clinical Trials Market is segmented as; Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial Data Management Services, Others.
By Region: This research also includes data for Australia, China, India, Japan, South Korea, Rest of Asia-Pacific.
According to SPER market research, ‘Europe Clinical Trials Market Size- By Phase, By Indication, By Study Design, By Service Type – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Europe Clinical Trials Market is predicted to reach 44.34 billion by 2034 with a CAGR of 7.11%.
Clinical trials represent an essential procedure in the creation of novel therapies or medical devices. These investigations assess new pharmaceuticals, medical devices, or additional therapeutic agents, establishing a scientific foundation for efficient patient care while determining the safety and effectiveness of these innovations. The surge in research and development efforts by pharmaceutical and biotechnology firms around the globe has resulted in a rise in the number of clinical studies.
Restraints:
A significant challenge faced by the European clinical trials market is the intricate nature of regulatory approval procedures. Countries within the European Union differ in their regulations, which can cause delays and elevate costs for pharmaceutical companies attempting to conduct clinical trials across several European countries. Despite initiatives aimed at harmonizing regulatory standards, such as those led by the European Medicines Agency (EMA), the variation in national regulations and bureaucratic obstacles continue to present substantial challenges.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Phase, By Indication, By Study Design, By Service Type
Regions covered
IQVIA HOLDINGS, INC, PAREXEL International Corporation, Pharmaceutical Product Development,
Companies Covered
IQVIA HOLDINGS, INC, PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC., Syneos Health Inc, Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Inc., Dr. Notghi Contract Research GmbH, Charite Research Organisation GmbH, Janssen Global Services, LLC, Mondosano GmbH, KFGN.
Europe Clinical Trials Market Segmentation:
By Phase: Based on the Phase, Europe Clinical Trials Market is segmented as; Phase I, Phase II, Phase III, Phase IV.
By Study Design: Based on the Study Design, Europe Clinical Trials Market is segmented as; Interventional studies, Observational studies, Expanded access studies.
By Indication: Based on the Indication, Europe Clinical Trials Market is segmented as; Autoimmune/inflammation, Pain management, Oncology, CNS conditions, Diabetes, Obesity, Cardiovascular, Others.
By Service Type: Based on the Service Type, Europe Clinical Trials Market is segmented as; Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial Data Management Services, Others.
By Region: This research also includes data for Australia, China, India, Japan, South Korea, Rest of Asia-Pacific.
Table of Contents
159 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Europe Clinical Trials Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Clinical Trials Market
- 7. Europe Clinical Trials Market, By Phase (USD Million) 2021-2034
- 7.1. Phase I
- 7.2. Phase II
- 7.3. Phase III
- 7.4. Phase IV
- 8. Europe Clinical Trials Market, By Study Design (USD Million) 2021-2034
- 8.1. Interventional studies
- 8.2. Observational studies
- 8.3. Expanded access studies
- 9. Europe Clinical Trials Market, By Indication (USD Million) 2021-2034
- 9.1. Autoimmune/inflammation
- 9.1.1. Rheumatoid arthritis
- 9.1.2. Multiple sclerosis
- 9.1.3. Osteoarthritis
- 9.1.4. Irritable Bowel Syndrome (IBS)
- 9.1.5. Others
- 9.2. Pain management
- 9.2.1. Chronic pain
- 9.2.2. Acute pain
- 9.3. Oncology
- 9.3.1. Blood cancer
- 9.3.2. Solid tumors
- 9.3.3. Other
- 9.4. CNS conditions
- 9.4.1. Epilepsy
- 9.4.2. Parkinson's Disease (PD)
- 9.4.3. Huntington's Disease
- 9.4.4. Stroke
- 9.4.5. Traumatic Brain Injury (TBI)
- 9.4.6. Amyotrophic Lateral Sclerosis (ALS)
- 9.4.7. Muscle regeneration
- 9.4.8. Others
- 9.5. Diabetes
- 9.6. Obesity
- 9.7. Cardiovascular
- 9.8. Others
- 10. Europe Clinical Trials Market, By Service Type (USD Million) 2021-2034
- 10.1. Protocol Designing
- 10.2. Site Identification
- 10.3. Patient Recruitment
- 10.4. Laboratory Services
- 10.5. Bioanalytical Testing Services
- 10.6. Clinical Trial Data Management Services
- 10.7. Others
- 11. Europe Clinical Trials Market, (USD Million) 2021-2034
- 11.1. Europe Clinical Trials Market Size and Market Share
- 12. Europe Clinical Trials Market, By Region, (USD Million) 2021-2034
- 12.1. France
- 12.2. Germany
- 12.3. Italy
- 12.4. Spain
- 12.5. United Kingdom
- 12.6. Rest of Europe
- 13. Company Profile
- 13.1. IQVIA HOLDINGS, INC
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. PAREXEL International Corporation
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Pharmaceutical Product Development (PPD) LLC
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Syneos Health Inc
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Eli Lilly and Company
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Novo Nordisk A/S
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Pfizer, Inc
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Dr. Notghi Contract Research GmbH
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Charite Research Organisation GmbH
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Janssen Global Services, LLC
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Mondosano GmbH
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
- 13.12. KFGN
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
- 13.13. Others
- 14. Conclusion
- 15. List of Abbreviations
- 16. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.